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Abstract 
The processing of the Amyloid Precursor Protein (APP) is a critical event in the 
formation of amyloid plaques which are composed of the 4kDa amyloid -peptide (A).  
Processing of APP occurs through a non-amyloidogenic pathway, mediated by initial -
secretase cleavage or through an amyloidogenic pathway via sequential cleavage by - 
and -secretase enzymes, which produces A peptides. Currently, the diagnosis of 
probable or possible Alzheimer’s disease (AD) is primarily based on neuropsychological 
and neuroradiological assessment. Recent reports indicate that platelet -secretase 
activity is moderately increased in patients with AD and mild cognitive impairment 
(MCI). To our knowledge platelet -secretase activity has not yet been explored in this 
context and estimation of the ratio of the activities of - and -secretase in platelets may 
represent a useful surrogate marker of the balance between the two pathways of APP 
metabolism and be of importance for the diagnosis of AD. We therefore considered it of 
interest to develop assays of platelet - and -secretase activities suitable for such clinical 
investigations. Application of these assays to a Swedish population failed to uncover an 
effect of AD or MCI on individual platelet secretase activities or the secretase ratio. 
However, we did observe an inverse correlation between plasma triacylglycerol levels 
and the secretase ratio. The results are discussed in the context of the clinical usefulness 
of the secretase ratio as a biochemical adjunct to the diagnosis of AD.  
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INTRODUCTION 
 
 Alzheimer’s disease (AD) is the most common form of late life dementia and is 
one of the leading causes of death in developed countries [1][2]. The clinical symptoms 
of the disease include a progressive decline in memory, judgement and cognitive 
function. Neurodegeneration, neurofibrillary tangles (NFTs) and the presence of senile or 
neuritic plaques in the brains of sufferers of the disease are the major pathological 
changes associated with AD [3].  The characteristic neuritic plaques of AD are composed 
of the 4kDa amyloid - peptide (A) [4][5] which is formed following the sequential 
cleavage of the Amyloid Precursor Protein (APP) by - and -secretase, in what is known 
as the amyloidogenic pathway of APP processing. APP is a membrane spanning 
glycoprotein which under normal circumstances is predominantly cleaved by -secretase, 
an ADAM (A Disintegrin And Metalloprotease) protein, to fragments other than A 
[6][7]. The processing of APP by -secretase precludes the accumulation of A peptide 
and is named the non-amyloidogenic pathway. The cleavage results in the release of a 
soluble APP fragment (sAPPα) which has reported neuroprotective functions [8]. The 
remaining C-terminal stub is subject to cleavage by the -secretase complex, which 
releases a small peptide known as p3 that is considered non amyloidogenic.  
Several members of the ADAM family, including ADAM9, ADAM10, ADAM17 
(TACE), ADAM19 and ADAM8, have demonstrable -secretase activity [9][10]. In 
contrast, the aspartyl protease beta-amyloid cleavage enzyme-1 (BACE 1) is the major 
source of -secretase activity [11][12][13]. A related protease, BACE 2 also possesses -
secretase activity [14], though this protease cleaves APP more efficiently at an alternative 
site located within the A region and may play a greater role in the prevention of 
formation of A peptide in cells that co-express BACE 1 and BACE 2 [15][16]. Greatest 
BACE 1 activity is present in the brain, particularly in the neurons [12][13]. Increases in 
both BACE 1 protein level and -secretase activity have been reported in AD brains 
relative to healthy controls [17][18][19][20]. Conversely, the level of -secretase activity 
has been reported to be lower in AD brains relative to healthy controls [19].  
 Several peripheral blood cells contain the required components for the processing 
of APP but platelets are the major source of A in the peripheral blood [21]. Studies have 
indicated that platelet APP processing pathways are altered in AD [22][23][24], with a 
shift towards the amyloidogenic pathway which appears to reflect the overall disease 
process. These results suggest that alterations in the levels and activities of the enzymes 
involved in platelet APP processing could potentially be useful in aiding diagnosis of 
AD.  Given that the amyloidogenic and non-amyloidogenic pathways represent two 
alternative and competing pathways for APP processing [25], it is probable that the ratio 
of their activities would be more informative than the respective - or - secretase 
activity alone.  From a diagnostic point of view, the secretase ratio would be a more 
powerful tool than either - or -secretase activity alone since it gives an integrative 
overview of both the amyloidogenic and non amyloidogenic pathways. 
 Up to now, the diagnosis of probable or possible AD is primarily based on 
neuropsychological and neuroradiological assessment. In some countries, biomarkers in 
the cerebrospinal fluid (CSF) such as A42 and total or phosphorylated tau are also used. 
A potential biomarker such as the platelet /-secretase activity ratio, which is readily 
accessible and relatively easily assayed, would significantly enhance and simplify the 
diagnosis of AD.  The possibility to use a biomarker supporting the clinical diagnosis is 
of great relevance for early detection of the disease and also for the evaluation and 
monitoring of potential therapies. 
 A recent study by Johnston et al has demonstrated a slightly increased -secretase 
activity in platelet membrane from AD patients relative to healthy controls [22]. Platelet 
ADAM 10 expression has been shown to be reduced in AD [23][24]. To the best of our 
knowledge, platelet -secretase activity has not yet been explored in AD patients or 
healthy controls.  
The aim of the present study was to investigate the levels of platelet - and -
secretase activity, and the ratio between those activities in healthy controls, mild 
cognitive impairment (MCI) and AD.  
 
 
MATERIALS AND METHODS 
 
The platelet - and -secretase activity was analysed in 30 healthy control 
subjects, 6 MCI patients and 20 patients with probable AD. The diagnosis of probable 
AD and MCI was made on the basis of the case history, clinical evaluation, magnetic 
resonance imaging studies, mini-mental state examination (MMSE) and 
neuropsychological assessment. The study was approved by the local ethics committee at 
Karolinska Institutet, Stockholm. Informed consent was obtained from all controls and 
patients, and the study was carried out in accordance with the Helsinki Declaration.  
Blood was taken into a 5ml EDTA collection tube. Within 30 minutes of 
collection, the blood was centrifuged at 1300 g for 15 minutes at 4°C.  The uppermost 
1.2ml of platelet rich plasma (PRP) was removed to a separate centrifuge tube. Two 
400µl aliquots of this PRP were transferred to 10ml centrifuge tubes for the analysis of 
platelet - and -secretase activity. A platelet count was performed on the remaining 
400µl of PRP using a Sysmex XE-5000 Automated Haematology Analyser. The aliquots 
of PRP were centrifuged at 4700 g for 15 minutes at 4°C to collect the platelets. The 
supernatants were removed completely and discarded. The samples were analysed using 
slight modifications to the protocols included in commercially available kits which are 
intended for the measurement of cellular - and -secretase activity.  The substrate for 
either assay is a short sequence of amino acids which includes the cleavage sites for - or 
-secretase and utilises the EDANS/DABCYL fluorometric reporter system. The rate of 
change in fluorescence is correlated to the enzymatic activity in the sample.   
The platelet pellet for the -secretase assay was resuspended in 500µl of a 25mM 
Tris-HCL buffer pH 8. The pellet for the analysis of -secretase activity was resuspended 
in 5mls of wash buffer (450mM Tris pH 7.4, 12mM NaCl, 1.5mM EDTA) and the 
platelets were recovered following centrifugation at 4700 g for 15 minutes at 4°C. The 
supernatant was discarded and the pellet was resuspended in 250µl of cell extraction 
buffer (R&D Systems UK, Component of kit FP002). An aliquot of this suspension was 
diluted 1/40 in the same buffer prior to assay. These dilutions were sufficient to ensure 
that the enzymatic activity would fall within the linear range for each assay which was 
previously established through analysis of - and -secretase activity in serial dilution of 
platelets from a 23 year old control subject.  Platelet - and -secretase activity was 
measured using commercially available kits (FP001, FP002) which were obtained from 
R&D systems UK. 50µl of diluted platelet suspension was transferred in triplicate to a 96 
well micro-plate (Nunc, Roskilde, Denmark). The addition of 50l of 2X Reaction buffer 
and 5l of the appropriate substrate ( YEVHHQKLV – -secretase, REEVNLDAEFKR – 
-secretase) to each well brought the final volume per well to 105l. Each plate also 
included (in triplicate) a 2g/ml Recombinant Human TACE Positive control and a 
2.5g/ml Recombinant Human BACE Positive control, which were both sourced from 
R&D Systems UK. Each plate contained three blanks. The blank well for the platelet -
secretase, and TACE Positive control contained 50l of 25mM Tris-HCL buffer pH 8, 
50l 2X Reaction buffer and 5l of -secretase substrate. The blank wells for the platelet 
-secretase and BACE Positive control contained 50l of Cell extraction buffer 
(Platelets) or 50l of a 50mM Tris-HCL, 150mM NaCl pH 7.5 buffer, (BACE Positive 
control) as well as 50l 2X Reaction Buffer and 5l -secretase substrate. The plate was 
tapped gently to mix and the increase in fluorescence over a 95 minute time period at 
37°C was followed using a Safire II Microplate reader with Magellan PC software (v6.3; 
Tecan Austria Gmbh, Austria). At each time-point, the fluorescence reading for the 
relevant blank (average of triplicates) was subtracted from the average fluorescence of 
the triplicate sample/control wells. The resultant values were plotted in a scatter diagram, 
with relative fluorescence units (RFU) on the Y-axis and time in minutes on the X-axis. 
For the -secretase assay, the initial rates during the 5-25 minute linear phase were 
calculated by least squares approximation and were expressed as ∆RFU/h/106 platelets. 
The linear phase for the -secretase assay began at 25 minutes and continued for the 
duration of the assay. The rate of change in RFU per minute over the 25-95 minute time 
interval was calculated by least squares approximation and expressed as ∆RFU/h/106 
platelets.  
The method was linear up to 39 x 106 platelets per well for the -secretase activity 
(Fig.1A) assay and 1.28 x 106 platelets per well for the -secretase activity assay 
(Fig.1B). The average intra-assay coefficient of variation of triplicates was 4.7% and 
3.3% respectively for the platelet - and -secretase activity assays. The interassay 
coefficient of variation for the platelet - and -secretase activity assays was 12.2% and 
5.2% respectively. 
All platelet secretase activity measurements were carried out on fresh samples and 
were fully completed within 5 hours of blood collection. 
Serum lipid profiles were obtained for 16 of the patients and CSF A levels were 
obtained for 18 of the patients. Lipid and CSF A levels measurements were carried out 
in the Clinical Chemistry laboratory at Huddinge University Hospital according to 
routine procedures.  
Student’s t-Test was used to test for statistically significant differences in results 
between the control and patient groups at the p  0.05 level of significance. The Pearson 
correlation test was used investigate possible relationships between the platelet secretase 
activities and age, MMSE score, CSF A levels, Total cholesterol, HDL cholesterol, LDL 
cholesterol and triglyceride levels. 
 
RESULTS 
 
Patients in the demented group were significantly older than those in the control 
group (P < 0.001), while there was no significant difference between the ages of the MCI 
and control group, or the MCI and dementia groups. There was a higher proportion of 
female subjects in the healthy control group than the MCI or AD groups (Table 1) but 
there was no significant effect of gender on the platelet secretase activity in any of the 
groups when tested using Students two tailed t-Test. The patients sampled in this study 
had a range of MMSE score (15-30), indicating relative heterogeneity in terms of disease 
progression (Table 1).    
Platelet membrane -secretase activity and -secretase activity were measured in 
fresh samples from healthy controls and subjects with MCI and probable AD as described 
in methods. Freezing and storage of platelet pellets at -70°C led to great variation in the 
levels of - and -secretase activity measured, when compared to the activities detected 
in a corresponding fresh sample. It is likely that this may be due to alterations in the 
physical properties of the platelet membrane as a result of the freeze-thawing process, as 
the platelet membrane integrity is known to be sensitive to temperature. Plasma was 
found to be a potent inhibitor of platelet -secretase activity, most likely due to the 
presence of endogenous protease inhibitors. There was a complete inhibition of -
secretase activity in platelet rich plasma. As a result of this, the accurate measurement of 
-secretase activity in the purified platelet pellet depended greatly on the complete 
removal of the platelet poor plasma prior to resuspension in the final assay buffer.  
The composition of the centrifuge tubes used in the platelet preparation steps was 
also found to have a significant effect on the levels of detected -secretase activity, most 
	
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This also raises the question of whether there 
is a relationship between secretase activities, 
product levels and the genotype of AAT 
likely because of small differences in the amount of residual platelet poor plasma left 
prior to resuspension in the assay buffer. During the course of this study, two different 
types of centrifuge tubes were used. One specific type of centrifuge tube was used in the 
preparation of the first 28 samples and a different type of centrifuge tube was used in the 
preparation of the remaining samples. The comparison of -secretase activity levels in 8 
samples that were prepared using both the old and new centrifuge tubes led to the finding 
that the detected -secretase activity was, on average, 1.45 times higher in the second 
type of centrifuge tubes. The calculated value (1.45) was used to normalise the data and 
allow for the comparison of levels of -secretase activity between the two different types 
of centrifuge tubes. The effect of centrifuge tube on platelet -secretase activity was 
minimal.  
There was no significant difference in the yield or the purity of the isolated 
platelets between the control and dementia groups or the control and MCI groups 
(Table.1). No significant effect of age or MMSE score on the -secretase activity, -
secretase activity or the -/-secretase activity ratio in either patient or control groups 
was observed (Table.2) There was no statistically significant difference between the 
levels of -secretase activity, -secretase activity or the derived secretase activity ratio in 
the MCI or dementia groups when compared to the healthy control group (Fig.2). 
There was no significant correlation observed between CSF A levels, total, HDL 
or LDL cholesterol and any secretase activity in the patients for whom these values were 
available (Table 2). However, a statistically significant correlation was observed between 
triglyceride levels and the -/-secretase activity ratio (Fig.3)  
 
DISCUSSION 
 
The general consensus is that the levels of - and -secretase protein and activity 
are altered in AD brains compared to healthy controls [17][18][19][20] but such tissue is 
only available at post mortem. Since CSF comes into direct contact with the extracellular 
spaces of the brain, it is attractive to use this as a source of biomarkers for neurological 
diseases. One recent investigation failed to demonstrate a significant difference between 
AD-patients and controls with respect to -secretase activity in CSF [26]. However the 
same study did report the finding of a slightly but significantly higher CSF -secretase 
activity in MCI than in AD or control group. One of the major drawbacks to analysis of 
CSF is the difficulty in obtaining a sample and the discomfort and stress caused to the 
patient by the sampling procedure. In contrast to this, a whole blood sample can be 
acquired with minimal invasiveness. Given that platelets express both - and -secretase 
they would appear to be a viable source of biomarkers for AD. To this end, the primary 
objective of this study was to establish assays for platelet - and -secretase activity and 
to test the hypothesis that these activities are affected by dementia and AD. 
  The levels of the -secretase ADAM 10 have been shown to be lower in platelets 
from AD patients than in healthy controls [23][24].To the best of our knowledge platelet 
-secretase activity has not previously been investigated in healthy controls or AD 
patients but it seems likely that expression levels would be correlated to activity. One 
group has recently reported elevated platelet -secretase activity in AD and MCI 
[22][27]. However, within our population we failed to demonstrate a significant effect of 
AD or MCI on either of the two activities or the ratio between the two activities. Potential 
explanations for the lack of agreement between the studies could be the different platelet 
preparation methodology used in the studies or differences in the disease states and 
demographics of the sample populations. The fact that our control group was 
significantly younger than our patient group could not explain our failure to demonstrate 
a difference between the groups since there was no significant effect of age on the 
platelet secretase activities in any of the groups (Table 2). However, our finding that 
plasma TAG levels are inversely correlated to the secretase activity ratio (cf below) may 
provide some explanation for this. 
Numerous studies have reported that cholesterol exerts a regulatory influence on 
APP processing and A formation. One recent study has demonstrated that reducing 
cellular cholesterol levels has an inhibitory effect on - and - secretase activity [28]. 
Another study reports an increased α- secretase activity after cholesterol depletion in 
several different cell lines [29]. Very recently Liu et al have reported that the absolute 
cholesterol levels may be important for the platelet BACE activity [30]. In the present 
study we could not detect any significant correlations between circulating cholesterol 
levels and platelet - or -secretase activity. However, despite the small sample size 
(n=16) we did find a statistically significant correlation between the levels of TAG and 
the -/-secretase activity ratio. It should be noted in this context that the correlation is 
between plasma lipid levels and activity, rather than platelet lipid level and activity. 
  The presence of a statistically significant correlation between TAG levels and 
platelet -secretase activity but not -secretase activity indicates that the relationship 
between TG and the -/-secretase activity ratio is mainly due to an effect on -secretase 
activity. In contrast to our results which suggest the existence of a relationship between 
TAG and -secretase activity, a recent cell-based study has tested the effect of several 
different TAGs on β-secretase activity in HEK cells stably expressing BACE-1 and found 
no significant effect [31]. The results of this study may however be confounded by the 
high level expression strategy dependent on an exogenous promoter which may 
circumvent normal homeostatic mechanisms. 
It should be pointed out that the -secretase assay measures overall activity and 
does not distinguish between various types of -secretase which may be present in 
platelets. Thus, we cannot exclude the possibility that the activity of one specific protein 
with -secretase activity could be decreased without a significant effect on the total 
platelet -secretase activity.  
Interestingly, several recent studies have implicated interleukins, including IL-1, 
with a role in upregulating the non-amyloidogenic pathway of APP processing, via 
upregulation of ADAM 10 and TACE [32][33]. One study has identified an increased 
plasma level of IL-1 in AD [34], which could potentially lead to a shift towards the non- 
amyloidogenic pathway in platelets. 
In conclusion, we have demonstrated that it is possible to kinetically assay both - 
and -secretase activity in human platelets. To the best of our knowledge, this is the first 
study to report the measurement of -secretase activity in human platelets. We have 
identified an apparent relationship between the level of TAG and platelet -secretase 
activity and hence the -/-secretase activity ratio which will require further 
investigation. If the existence of such a relationship is confirmed, it is possible that it may 
be necessary to normalise the -secretase activity with respect to TAG levels before 
testing for differences in secretase activities between patient and control groups. It would 
also be of interest to directly investigate the effect of specific species of TAG on platelet 
-secretase activity.  
  In the present study we were unable to uncover any significant differences in the 
levels of the secretase activities in health, MCI or dementia. Given the relatively small 
number of patient and control samples in our study, and the positive studies previously 
published, we can not completely exclude an effect of neurodegenerative diseases on the 
platelet - and/or -secretase activities. If such an effect exists, however, it is likely to be 
small and at this stage it is difficult to assess its usefulness for routine diagnostic 
purposes. 
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Figure Legends 
 
Fig.1. Linearity studies for platelet - and -secretase activity. 
(A) Platelet -secretase activity increased linearly up to 39*106 platelets per well (R2 = 
0.9943). (B) Platelet -secretase activity increased linearly up to 1.28*106 platelets per 
well (R2 = 0.9908). 
 
Fig.2. Platelet secretase activity stratified by diagnosis. HC = healthy controls, MCI =  
mild cognitive impairment and AD = Alzheimer disease. Secretase activities are 
expressed as ∆RFU/h/106 platelets.  
 
Fig.3. Plasma triacylglycerol levels are inversely correlated with the platelet secretase 
activity ratio in Alzheimer disease patients. Open circles = male, filled circles = female.   
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 Table.1. Sample population characteristics and platelet secretase activity results. 
˚ Values are expressed as Mean ± Standard Deviation of Mean 
* % Purity was calculated by expressing the number of platelets as a percentage of total  
number of platelets + red blood cells + white blood cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group n Age˚ 
(years) 
Gender 
(F:M) 
MMSE˚ Platelet 
Yield˚ 
(*10^9/L) 
Purity* (%) -secretase 
activity˚ 
(∆RFU/h/106 
platelets) 
-secretase 
activity˚ 
(∆RFU/h/106 
platelets) 
-/-secretase 
activity ratio˚ 
Controls 30 61.7 ± 7.5 23 : 7 NA 269 ± 65 93.8 ± 5.6 37.6 ± 6.9 279 ± 57 0.1396 ± 0.0343 
AD 20 71.6 ± 9.8 10 : 10 24 ± 3 290 ± 96 95.1 ± 2.7 36.2 ± 5.8 285 ± 52 0.1317 ± 0.0342 
MCI 6 65.7 ± 9.8 3 : 3 27.6 ± 2.1 268 ± 71 96.2 ± 2.0 34.9 ± 2.1 246 ± 42 0.1458 ± 0.0284 
 Variable n α-secretase 
activity 
β-secretase 
activity 
α/β Secretase 
Activity Ratio 
     
Age (AD) 
 
20 
 
 = 0.23 
P = N.S 
 = -0.19 
P = N.S 
 = 0.24 
P = N.S 
MMSE 
 
24 
 
 = 0.12 
P = N.S 
 = 0.00 
P = N.S 
 = 0.10 
P = N.S 
CSF A 
 
18 
 
 = -0.11 
P = N.S 
 = -0.20 
P = N.S 
 = 0.07 
P = N.S 
Total Cholesterol 
 
16 
 
 = -0.29 
P = N.S 
 = 0.07 
P = N.S 
 = -0.26 
P = N.S 
HDL Cholesterol 
 
16 
 
 = -0.23 
P = N.S 
 = -0.22 
P = N.S 
 = -0.11 
P = N.S 
LDL Cholesterol 
 
16 
 
 = -0.29 
P = N.S 
 = -0.02 
P = N.S 
 = -0.11 
P = N.S 
Triglycerides 16  = -0.34 
P = N.S. 
 = 0.51 
P = < 0.05 
 = -0.67 
P = < 0.01 
 
Table 2. Relationship between platelet secretase activities and variables including Age, MMSE 
Score, CSF A, Total Cholesterol, HDL Cholesterol, LDL Cholesterol and Triglyceride levels. 
Correlation was tested for using the Pearson correlation test. The level of significance was set at 
P  0.05. N.S = Not Significant  
 
 
 
 
 
 
 
 
 
